Table 1.
Patient characteristics
| ADA positive N=21 |
ADA negative N=36 |
P value | |
| Age at diagnosis, years (SD) | 22.0 (7.9) | 30.0 (11.8) | <0.001*** |
| Age at time of treatment, years (SD) | 31.9 (9.1) | 42.9 (11.1) | 0.03* |
| Disease duration, months (SD) | 119 (76) | 151 (108) | NS |
| Gender (Female:Male) (%) | 16:5 (76:24) | 34:2 (94:6) | 0.04* |
| Ethnicity, n (%) | |||
| Afro-Caribbean | 5 (24) | 6 (17) | NS |
| Caucasian | 9 (43) | 19 (53) | NS |
| South Asian | 3 (14) | 6 (17) | NS |
| East Asian | 3 (14) | 2 (5) | NS |
| Other | 1 (5) | 3 (8) | NS |
| Indication for treatment, n (%) | |||
| Nephritis | 10 (48) | 7 (19) | NS |
| Arthritis | 5 (24) | 11 (31) | NS |
| Haematological | 3 (14) | 2 (6) | NS |
| Neuro-psychiatric | 0 (0) | 1 (3) | NS |
| Serositis | 1 (5) | 3 (8) | NS |
| Cutaneous | 6 (29) | 9 (25) | NS |
| Other | 3 (14) | 3 (8) | NS |
| Additional treatment, n (%) | |||
| Hydroxychloroquine | 10 (48) | 20 (56) | NS |
| Azathioprine | 5 (24) | 5 (14) | NS |
| Mycophenolate mofetil | 4 (19) | 4 (11) | NS |
| Methotrexate | 0 (0) | 4 (11) | NS |
| Prednisolone | 17 (81) | 27 (75) | NS |
| Cyclophosphamide† | 15 (71) | 22 (61) | NS |
| Disease activity at the time of treatment | |||
| Complement C3 (g/L) (SD) | 0.76 (0.29) | 0.69 (0.24) | NS |
| Anti-dsDNA titres (IU) (SD) | 411.7 (651.6) | 699.8 (874.2) | NS |
| Global BILAG score (SD) | 15.8 (10.2) | 13.5 (5.6) | NS |
| Disease activity 6 months post-treatment | |||
| Complement C3 (g/L) (SD) | 0.91 (0.27) | 0.83 (0.24) | NS |
| Anti-dsDNA titres (IU) (SD) | 201.4 (369.6) | 682.0 (1009.0) | 0.04* |
| Global BILAG score (SD) | 6.4 (5.4) | 7.4 (5.4) | NS |
*p<0.05; ***p<0.001.
†Given in combination with rituximab therapy.
ADA, antidrug antibody;BILAG, British Isles Lupus Assessment Group; dsDNA, double-stranded DNA; NS, not significant.